RESUMEN
Pancreatic cancer is relatively uncommon and carries a poor prognosis because patients often develop signs or symptoms at a late stage of illness. Patients with a family history, especially those with genetic syndromes, are at a significantly increased risk of pancreatic cancer. Modifiable risk factors include smoking, heavy alcohol use, and obesity. Although patients at increased risk should be screened, screening is not recommended for asymptomatic people at average risk. The differential diagnosis for a symptomatic patient is broad, including gastroesophageal reflux disease, gastritis, peptic ulcer disease, chronic pancreatitis, biliary dyskinesia, cholelithiasis, gastroparesis, or constipation. Initial serologic testing should include transaminase and bilirubin levels, and in patients with midepigastric pain, lipase levels. Pancreas-protocol, contrast-enhanced abdominal computed tomography is the imaging test of choice. Carbohydrate antigen 19-9 is the most studied cancer marker and moderately accurate in patients suspected of having cancer; however, the positive predictive value is 0.9% in asymptomatic patients. Treatment includes neoadjuvant or adjuvant chemotherapy and surgery if the cancer is resectable. The treatment approach is best determined by a multidisciplinary, high-volume center. For a patient undergoing chemotherapy, nutritional and psychosocial support and palliation of symptoms should be goals during treatment.
Asunto(s)
Neoplasias Pancreáticas , Pancreatitis Crónica , Humanos , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/terapia , Páncreas , Factores de Riesgo , Pancreatitis Crónica/diagnóstico , Pancreatitis Crónica/etiología , Pancreatitis Crónica/terapia , Tomografía Computarizada por Rayos XRESUMEN
Barrett esophagus is a premalignant change of the esophagus; however, malignant transformation to esophageal adenocarcinoma is rare in patients without dysplasia. Barrett esophagus is estimated to affect up to 5.6% of the U.S. population. Risk factors for Barrett esophagus include gastroesophageal reflux disease, obesity, age older than 50 years, male sex, tobacco use, and a family history of Barrett esophagus or esophageal adenocarcinoma. Patients who experience chronic gastroesophageal reflux symptoms plus additional risk factors should be considered for screening. Mucosal change consistent with Barrett esophagus is visualized during upper endoscopy; biopsy confirms the diagnosis and determines if dysplasia is present. Management of Barrett esophagus depends on the presence and severity of dysplasia; endoscopic treatment of dysplasia decreases the risk of malignant transformation. Surveillance after diagnosis is recommended to monitor for dysplasia and diagnose and treat esophageal adenocarcinoma at an earlier stage. Patients with Barrett esophagus should be offered proton pump inhibitor therapy to control reflux symptoms and possibly decrease the risk of developing esophageal adenocarcinoma. Statins, nonsteroidal anti-inflammatory drugs, and aspirin are associated with a decreased risk of esophageal adenocarcinoma in patients with Barrett esophagus; however, they should not generally be prescribed in the absence of another indication. Mortality benefits of screening and surveillance are uncertain.
Asunto(s)
Adenocarcinoma , Esófago de Barrett , Neoplasias Esofágicas , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Lesiones Precancerosas , Humanos , Masculino , Persona de Mediana Edad , Esófago de Barrett/terapia , Esófago de Barrett/tratamiento farmacológico , Inhibidores de la Bomba de Protones/uso terapéutico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Lesiones Precancerosas/diagnóstico , Lesiones Precancerosas/tratamiento farmacológico , Lesiones Precancerosas/patología , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/etiología , Neoplasias Esofágicas/prevención & control , Adenocarcinoma/diagnóstico , Adenocarcinoma/etiología , Adenocarcinoma/prevención & control , Aspirina/uso terapéutico , Antiinflamatorios/uso terapéuticoRESUMEN
The complexity of this disorder poses a clinical challenge like few others.
Asunto(s)
Enfermedades del Sistema Nervioso/diagnóstico , Enfermedades del Sistema Nervioso/fisiopatología , Diagnóstico Diferencial , Humanos , Enfermedades del Sistema Nervioso/terapia , Examen FísicoAsunto(s)
Pólipos del Colon/diagnóstico , Colonografía Tomográfica Computarizada/normas , Neoplasias Colorrectales/diagnóstico , Detección Precoz del Cáncer/métodos , Atención Primaria de Salud/organización & administración , Neoplasias Colorrectales/prevención & control , Femenino , Humanos , Masculino , Tamizaje Masivo/normasAsunto(s)
Encéfalo/diagnóstico por imagen , Neurocisticercosis/complicaciones , Convulsiones/etiología , Adulto , Animales , Anticuerpos Antihelmínticos/análisis , Diagnóstico Diferencial , Humanos , Imagen por Resonancia Magnética , Masculino , Neurocisticercosis/diagnóstico , Neurocisticercosis/parasitología , Convulsiones/diagnóstico , Taenia solium/inmunología , Tomografía Computarizada por Rayos XRESUMEN
An estimated 15% of children in the United States have at least one developmental delay, yet less than one-fifth of those children receive early intervention services before three years of age. Many barriers exist to implementing initial screening and referral, but screening tools can be easily incorporated into the workflow of the primary care practice with preparation. The use of a validated screening tool at regular, repeated intervals, in addition to physician surveillance at well-child visits, may improve early detection. Early intervention is effective in high-risk children and associated with improvements in cognitive and academic performance. Parent-completed tools are preferable to directly administered tools in the primary care setting because of time constraints. The most extensively evaluated parentcompleted tools are the Ages and Stages Questionnaire and the Parents' Evaluation of Developmental Status. Family physicians should be familiar with currently available screening tools and the limitations and strengths of these tools. Additional evaluations and referrals are recommended if screening suggests developmental delays are present.